Navigation Links
Pharmatech Oncology Announces Completion of SBIR Grant Research

DENVER, Oct. 20, 2011 /PRNewswire/ -- Pharmatech Oncology announces completion of a phase I Small Business Innovative Research (SBIR) grant project, funded by the National Cancer Institute (NCI). 

The SBIR grant project evaluated Pharmatech Oncology's innovative enrollment model called Just-in-Time (JIT) to enroll cancer patients into clinical trials.  The JIT model is prioritized around detection of patients with qualifying diagnoses across many research practices. Patients who meet study entry criteria and have interest in receiving the investigational treatment are enrolled into the trial within two weeks through rapid regulatory activation of their care center as a study site.  JIT is a patient-focused approach designed to align clinical research with cancer patient care as it is currently delivered in the US.

The SBIR project evaluated the feasibility and efficiency of JIT in five separate studies, comparing the research performance of JIT-initiated sites to traditionally managed sites in retrospective analyses.  JIT demonstrated advantages in several important areas:

  • Higher patient enrollment rates (3.1x greater at six months)
  • Fewer non-enrolling sites (77% reduction)
  • Reduced time to first patient enrolled  (79-95% fewer days)
  • Lower administrative cost per site
  • No reduction of patient safety or data quality

"The SBIR phase I results have significant implications for the commercial development of the JIT model," remarked Dr. Matthew Wiener, Pharmatech founder.  "The positive impact on the clinical trials we've evaluated has been profound. With this essential validation of the methodology we are beginning to see awareness and adaptation of JIT increase among study centers and sponsors, which is critical to the growth of JIT as a commercial research solution." Pharmatech Oncology has submitted an application for a new SBIR grant to fund a phase II program with the aim to develop the JIT model further toward such commercialization.  Dr. Wiener comments, "Our vision for JIT is that any cancer patient and oncologist in any research-capable practice should have access to all appropriate treatment options, including clinical trials."

About Pharmatech Oncology, Inc.:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) with a focus on oncology clinical research. Through an organized network of cancer clinics, the Company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and on promoting the inclusion of clinical trials in the spectrum of patient treatment options.

For more information about Pharmatech, please visit

The project described was supported by Award Number R43CA144362 from the National Cancer institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

SOURCE Pharmatech Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Congratulates the 2010 Nobel Laureates in Chemistry
2. Quest PharmaTech Announces Formation of Clinical Advisory Panel
3. Pharmatech Oncology to Present at 46th Annual DIA Meeting
4. Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial
5. WuXi PharmaTech Files 2009 Annual Report on Form 20-F
6. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2009 Results
7. WuXi PharmaTech (NYSE: WX) Holds Its Third Life Science and Chemistry Awards Ceremony in Beijing
8. WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening
9. WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
10. Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
11. WuXi PharmaTech Announces Second-Quarter 2009 Results
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for ... of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference ... ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... ... 2015 , ... This fall, global software solutions leader SAP and AdVenture Capital ... and pitch their BIG ideas to improve health and wellness in their schools. , ... win the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl ...
(Date:11/24/2015)...  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General ... a.m. Israel time, at the law offices of ... 36 th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election ... , approval of an amendment to certain terms of options granted to ...
(Date:11/24/2015)... ... ... InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and ... as Chief Operating Officer. , Having joined InSphero in November 2013 as ... promoted to Head of InSphero Diagnostics in 2014. There she has built up ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
(Date:11/4/2015)... November 4, 2015 --> ... report published by Transparency Market Research "Home Security Solutions Market ... Forecast 2015 - 2022", the global home security solutions market is ... by 2022. The market is estimated to expand at ... 2015 to 2022. Rising security needs among customers at ...
(Date:10/29/2015)... JOLLA, Calif. , Oct. 29, 2015  The ... a new report titled, "DNA Synthesis and Biosecurity: Lessons ... well the Department of Health and Human Services guidance ... issued in 2010. --> ... but it also has the potential to pose unique ...
Breaking Biology News(10 mins):